nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluorouracil—head and neck cancer—bone cancer	0.204	0.362	CtDrD
Fluorouracil—breast cancer—bone cancer	0.193	0.343	CtDrD
Fluorouracil—skin cancer—bone cancer	0.167	0.296	CtDrD
Fluorouracil—ABCC5—Cisplatin—bone cancer	0.0504	0.169	CbGbCtD
Fluorouracil—MTHFR—Methotrexate—bone cancer	0.0466	0.156	CbGbCtD
Fluorouracil—TYMS—Methotrexate—bone cancer	0.0397	0.133	CbGbCtD
Fluorouracil—ABCC3—Cisplatin—bone cancer	0.0317	0.106	CbGbCtD
Fluorouracil—ABCC3—Doxorubicin—bone cancer	0.0212	0.0712	CbGbCtD
Fluorouracil—ABCC3—Methotrexate—bone cancer	0.0206	0.069	CbGbCtD
Fluorouracil—SLC22A7—Methotrexate—bone cancer	0.0161	0.054	CbGbCtD
Fluorouracil—ABCC4—Methotrexate—bone cancer	0.0157	0.0527	CbGbCtD
Fluorouracil—ABCG2—Carboplatin—bone cancer	0.0152	0.0511	CbGbCtD
Fluorouracil—ABCG2—Cisplatin—bone cancer	0.013	0.0437	CbGbCtD
Fluorouracil—ABCG2—Doxorubicin—bone cancer	0.00872	0.0293	CbGbCtD
Fluorouracil—ABCG2—Methotrexate—bone cancer	0.00845	0.0284	CbGbCtD
Fluorouracil—ALB—Methotrexate—bone cancer	0.00583	0.0195	CbGbCtD
Fluorouracil—CYP2C9—Cisplatin—bone cancer	0.00484	0.0162	CbGbCtD
Fluorouracil—UMPS—Doxorubicin—Epirubicin—bone cancer	0.000382	0.173	CbGdCrCtD
Fluorouracil—UMPS—Idarubicin—Epirubicin—bone cancer	0.000382	0.173	CbGdCrCtD
Fluorouracil—UMPS—Daunorubicin—Epirubicin—bone cancer	0.000382	0.173	CbGdCrCtD
Fluorouracil—UMPS—Epirubicin—Doxorubicin—bone cancer	0.000353	0.16	CbGdCrCtD
Fluorouracil—UMPS—Idarubicin—Doxorubicin—bone cancer	0.000353	0.16	CbGdCrCtD
Fluorouracil—UMPS—Daunorubicin—Doxorubicin—bone cancer	0.000353	0.16	CbGdCrCtD
Fluorouracil—Herpes simplex—Doxorubicin—bone cancer	0.000157	0.00278	CcSEcCtD
Fluorouracil—Dermatitis contact—Epirubicin—bone cancer	0.000155	0.00274	CcSEcCtD
Fluorouracil—Dysarthria—Doxorubicin—bone cancer	0.000153	0.00271	CcSEcCtD
Fluorouracil—Ulcer—Doxorubicin—bone cancer	0.000153	0.00271	CcSEcCtD
Fluorouracil—Coma—Methotrexate—bone cancer	0.000153	0.00271	CcSEcCtD
Fluorouracil—Inflammation—Doxorubicin—bone cancer	0.000149	0.00265	CcSEcCtD
Fluorouracil—Sepsis—Methotrexate—bone cancer	0.000145	0.00257	CcSEcCtD
Fluorouracil—Dermatitis contact—Doxorubicin—bone cancer	0.000143	0.00254	CcSEcCtD
Fluorouracil—Coma—Epirubicin—bone cancer	0.000143	0.00253	CcSEcCtD
Fluorouracil—Oesophagitis—Epirubicin—bone cancer	0.000143	0.00253	CcSEcCtD
Fluorouracil—Rash maculo-papular—Epirubicin—bone cancer	0.000142	0.00252	CcSEcCtD
Fluorouracil—Thrombophlebitis—Methotrexate—bone cancer	0.00014	0.00249	CcSEcCtD
Fluorouracil—Photosensitivity—Methotrexate—bone cancer	0.000138	0.00245	CcSEcCtD
Fluorouracil—Arrhythmia—Cisplatin—bone cancer	0.000137	0.00242	CcSEcCtD
Fluorouracil—Sepsis—Epirubicin—bone cancer	0.000136	0.00241	CcSEcCtD
Fluorouracil—Alopecia—Cisplatin—bone cancer	0.000135	0.0024	CcSEcCtD
Fluorouracil—Erythema—Cisplatin—bone cancer	0.000133	0.00236	CcSEcCtD
Fluorouracil—Coma—Doxorubicin—bone cancer	0.000132	0.00234	CcSEcCtD
Fluorouracil—Oesophagitis—Doxorubicin—bone cancer	0.000132	0.00234	CcSEcCtD
Fluorouracil—Rash maculo-papular—Doxorubicin—bone cancer	0.000132	0.00233	CcSEcCtD
Fluorouracil—Thrombophlebitis—Epirubicin—bone cancer	0.000131	0.00233	CcSEcCtD
Fluorouracil—Photosensitivity—Epirubicin—bone cancer	0.00013	0.00229	CcSEcCtD
Fluorouracil—Sepsis—Doxorubicin—bone cancer	0.000126	0.00223	CcSEcCtD
Fluorouracil—Vision blurred—Cisplatin—bone cancer	0.000126	0.00223	CcSEcCtD
Fluorouracil—Lethargy—Methotrexate—bone cancer	0.000124	0.0022	CcSEcCtD
Fluorouracil—Anaemia—Cisplatin—bone cancer	0.000123	0.00218	CcSEcCtD
Fluorouracil—Thrombophlebitis—Doxorubicin—bone cancer	0.000122	0.00215	CcSEcCtD
Fluorouracil—Osteoarthritis—Methotrexate—bone cancer	0.000122	0.00215	CcSEcCtD
Fluorouracil—Photosensitivity—Doxorubicin—bone cancer	0.00012	0.00212	CcSEcCtD
Fluorouracil—Leukopenia—Cisplatin—bone cancer	0.000119	0.00211	CcSEcCtD
Fluorouracil—Dermatitis bullous—Epirubicin—bone cancer	0.000119	0.00211	CcSEcCtD
Fluorouracil—Cardiac failure—Epirubicin—bone cancer	0.000117	0.00206	CcSEcCtD
Fluorouracil—Lethargy—Epirubicin—bone cancer	0.000116	0.00205	CcSEcCtD
Fluorouracil—Irritability—Methotrexate—bone cancer	0.000116	0.00205	CcSEcCtD
Fluorouracil—Convulsion—Cisplatin—bone cancer	0.000116	0.00205	CcSEcCtD
Fluorouracil—Ataxia—Methotrexate—bone cancer	0.000114	0.00202	CcSEcCtD
Fluorouracil—Osteoarthritis—Epirubicin—bone cancer	0.000114	0.00201	CcSEcCtD
Fluorouracil—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000114	0.00201	CcSEcCtD
Fluorouracil—Myalgia—Cisplatin—bone cancer	0.000114	0.00201	CcSEcCtD
Fluorouracil—Discomfort—Cisplatin—bone cancer	0.000112	0.00199	CcSEcCtD
Fluorouracil—Dermatitis bullous—Doxorubicin—bone cancer	0.00011	0.00195	CcSEcCtD
Fluorouracil—Anaphylactic shock—Cisplatin—bone cancer	0.000109	0.00193	CcSEcCtD
Fluorouracil—Oedema—Cisplatin—bone cancer	0.000109	0.00193	CcSEcCtD
Fluorouracil—Cardiac arrest—Epirubicin—bone cancer	0.000108	0.00191	CcSEcCtD
Fluorouracil—Infection—Cisplatin—bone cancer	0.000108	0.00191	CcSEcCtD
Fluorouracil—Cardiac failure—Doxorubicin—bone cancer	0.000108	0.00191	CcSEcCtD
Fluorouracil—Lethargy—Doxorubicin—bone cancer	0.000107	0.0019	CcSEcCtD
Fluorouracil—Ataxia—Epirubicin—bone cancer	0.000107	0.00189	CcSEcCtD
Fluorouracil—Nervous system disorder—Cisplatin—bone cancer	0.000107	0.00189	CcSEcCtD
Fluorouracil—Thrombocytopenia—Cisplatin—bone cancer	0.000107	0.00189	CcSEcCtD
Fluorouracil—Tachycardia—Cisplatin—bone cancer	0.000106	0.00188	CcSEcCtD
Fluorouracil—Osteoarthritis—Doxorubicin—bone cancer	0.000105	0.00186	CcSEcCtD
Fluorouracil—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000105	0.00186	CcSEcCtD
Fluorouracil—Dry skin—Epirubicin—bone cancer	0.000104	0.00185	CcSEcCtD
Fluorouracil—Eosinophilia—Methotrexate—bone cancer	0.000104	0.00184	CcSEcCtD
Fluorouracil—Anorexia—Cisplatin—bone cancer	0.000104	0.00184	CcSEcCtD
Fluorouracil—Hypotension—Cisplatin—bone cancer	0.000102	0.0018	CcSEcCtD
Fluorouracil—Nasopharyngitis—Epirubicin—bone cancer	0.000102	0.0018	CcSEcCtD
Fluorouracil—Muscular weakness—Epirubicin—bone cancer	0.0001	0.00178	CcSEcCtD
Fluorouracil—Cardiac arrest—Doxorubicin—bone cancer	0.0001	0.00177	CcSEcCtD
Fluorouracil—Pancytopenia—Methotrexate—bone cancer	9.98e-05	0.00177	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Cisplatin—bone cancer	9.92e-05	0.00176	CcSEcCtD
Fluorouracil—Ataxia—Doxorubicin—bone cancer	9.9e-05	0.00175	CcSEcCtD
Fluorouracil—Dysphagia—Epirubicin—bone cancer	9.83e-05	0.00174	CcSEcCtD
Fluorouracil—Paraesthesia—Cisplatin—bone cancer	9.78e-05	0.00173	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Methotrexate—bone cancer	9.76e-05	0.00173	CcSEcCtD
Fluorouracil—Eosinophilia—Epirubicin—bone cancer	9.73e-05	0.00172	CcSEcCtD
Fluorouracil—Dyspnoea—Cisplatin—bone cancer	9.71e-05	0.00172	CcSEcCtD
Fluorouracil—Dry skin—Doxorubicin—bone cancer	9.65e-05	0.00171	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Methotrexate—bone cancer	9.59e-05	0.0017	CcSEcCtD
Fluorouracil—Angina pectoris—Epirubicin—bone cancer	9.58e-05	0.0017	CcSEcCtD
Fluorouracil—Decreased appetite—Cisplatin—bone cancer	9.46e-05	0.00168	CcSEcCtD
Fluorouracil—Pneumonia—Methotrexate—bone cancer	9.42e-05	0.00167	CcSEcCtD
Fluorouracil—Nasopharyngitis—Doxorubicin—bone cancer	9.41e-05	0.00167	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Cisplatin—bone cancer	9.4e-05	0.00166	CcSEcCtD
Fluorouracil—Infestation NOS—Methotrexate—bone cancer	9.37e-05	0.00166	CcSEcCtD
Fluorouracil—Infestation—Methotrexate—bone cancer	9.37e-05	0.00166	CcSEcCtD
Fluorouracil—Pancytopenia—Epirubicin—bone cancer	9.34e-05	0.00165	CcSEcCtD
Fluorouracil—Pain—Cisplatin—bone cancer	9.31e-05	0.00165	CcSEcCtD
Fluorouracil—Muscular weakness—Doxorubicin—bone cancer	9.28e-05	0.00164	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Epirubicin—bone cancer	9.14e-05	0.00162	CcSEcCtD
Fluorouracil—Stomatitis—Methotrexate—bone cancer	9.13e-05	0.00162	CcSEcCtD
Fluorouracil—Conjunctivitis—Methotrexate—bone cancer	9.11e-05	0.00161	CcSEcCtD
Fluorouracil—Dysphagia—Doxorubicin—bone cancer	9.1e-05	0.00161	CcSEcCtD
Fluorouracil—Eosinophilia—Doxorubicin—bone cancer	9.01e-05	0.00159	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Epirubicin—bone cancer	8.97e-05	0.00159	CcSEcCtD
Fluorouracil—Feeling abnormal—Cisplatin—bone cancer	8.97e-05	0.00159	CcSEcCtD
Fluorouracil—Angina pectoris—Doxorubicin—bone cancer	8.86e-05	0.00157	CcSEcCtD
Fluorouracil—Epistaxis—Methotrexate—bone cancer	8.84e-05	0.00156	CcSEcCtD
Fluorouracil—Pneumonia—Epirubicin—bone cancer	8.82e-05	0.00156	CcSEcCtD
Fluorouracil—Infestation NOS—Epirubicin—bone cancer	8.77e-05	0.00155	CcSEcCtD
Fluorouracil—Infestation—Epirubicin—bone cancer	8.77e-05	0.00155	CcSEcCtD
Fluorouracil—Agranulocytosis—Methotrexate—bone cancer	8.74e-05	0.00155	CcSEcCtD
Fluorouracil—Pancytopenia—Doxorubicin—bone cancer	8.64e-05	0.00153	CcSEcCtD
Fluorouracil—Body temperature increased—Cisplatin—bone cancer	8.61e-05	0.00152	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Epirubicin—bone cancer	8.59e-05	0.00152	CcSEcCtD
Fluorouracil—Stomatitis—Epirubicin—bone cancer	8.54e-05	0.00151	CcSEcCtD
Fluorouracil—Conjunctivitis—Epirubicin—bone cancer	8.52e-05	0.00151	CcSEcCtD
Fluorouracil—Urinary tract infection—Epirubicin—bone cancer	8.52e-05	0.00151	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Doxorubicin—bone cancer	8.45e-05	0.0015	CcSEcCtD
Fluorouracil—Haemoglobin—Methotrexate—bone cancer	8.45e-05	0.0015	CcSEcCtD
Fluorouracil—Haemorrhage—Methotrexate—bone cancer	8.41e-05	0.00149	CcSEcCtD
Fluorouracil—Pharyngitis—Methotrexate—bone cancer	8.35e-05	0.00148	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Doxorubicin—bone cancer	8.3e-05	0.00147	CcSEcCtD
Fluorouracil—Epistaxis—Epirubicin—bone cancer	8.27e-05	0.00146	CcSEcCtD
Fluorouracil—Sinusitis—Epirubicin—bone cancer	8.22e-05	0.00146	CcSEcCtD
Fluorouracil—Agranulocytosis—Epirubicin—bone cancer	8.18e-05	0.00145	CcSEcCtD
Fluorouracil—Pneumonia—Doxorubicin—bone cancer	8.16e-05	0.00144	CcSEcCtD
Fluorouracil—Infestation NOS—Doxorubicin—bone cancer	8.11e-05	0.00144	CcSEcCtD
Fluorouracil—Infestation—Doxorubicin—bone cancer	8.11e-05	0.00144	CcSEcCtD
Fluorouracil—Hypersensitivity—Cisplatin—bone cancer	8.02e-05	0.00142	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Doxorubicin—bone cancer	7.95e-05	0.00141	CcSEcCtD
Fluorouracil—Haemoglobin—Epirubicin—bone cancer	7.91e-05	0.0014	CcSEcCtD
Fluorouracil—Stomatitis—Doxorubicin—bone cancer	7.91e-05	0.0014	CcSEcCtD
Fluorouracil—Rhinitis—Epirubicin—bone cancer	7.89e-05	0.0014	CcSEcCtD
Fluorouracil—Urinary tract infection—Doxorubicin—bone cancer	7.88e-05	0.0014	CcSEcCtD
Fluorouracil—Conjunctivitis—Doxorubicin—bone cancer	7.88e-05	0.0014	CcSEcCtD
Fluorouracil—Haemorrhage—Epirubicin—bone cancer	7.87e-05	0.00139	CcSEcCtD
Fluorouracil—Hypoaesthesia—Epirubicin—bone cancer	7.83e-05	0.00139	CcSEcCtD
Fluorouracil—Pharyngitis—Epirubicin—bone cancer	7.81e-05	0.00138	CcSEcCtD
Fluorouracil—Epistaxis—Doxorubicin—bone cancer	7.65e-05	0.00135	CcSEcCtD
Fluorouracil—Sinusitis—Doxorubicin—bone cancer	7.61e-05	0.00135	CcSEcCtD
Fluorouracil—Agranulocytosis—Doxorubicin—bone cancer	7.57e-05	0.00134	CcSEcCtD
Fluorouracil—Diarrhoea—Cisplatin—bone cancer	7.45e-05	0.00132	CcSEcCtD
Fluorouracil—Alopecia—Methotrexate—bone cancer	7.43e-05	0.00132	CcSEcCtD
Fluorouracil—Erythema—Methotrexate—bone cancer	7.32e-05	0.0013	CcSEcCtD
Fluorouracil—Haemoglobin—Doxorubicin—bone cancer	7.32e-05	0.0013	CcSEcCtD
Fluorouracil—Rhinitis—Doxorubicin—bone cancer	7.3e-05	0.00129	CcSEcCtD
Fluorouracil—Haemorrhage—Doxorubicin—bone cancer	7.28e-05	0.00129	CcSEcCtD
Fluorouracil—Hypoaesthesia—Doxorubicin—bone cancer	7.24e-05	0.00128	CcSEcCtD
Fluorouracil—Pharyngitis—Doxorubicin—bone cancer	7.23e-05	0.00128	CcSEcCtD
Fluorouracil—Arrhythmia—Epirubicin—bone cancer	7.03e-05	0.00124	CcSEcCtD
Fluorouracil—Alopecia—Epirubicin—bone cancer	6.95e-05	0.00123	CcSEcCtD
Fluorouracil—Vomiting—Cisplatin—bone cancer	6.92e-05	0.00123	CcSEcCtD
Fluorouracil—Vision blurred—Methotrexate—bone cancer	6.9e-05	0.00122	CcSEcCtD
Fluorouracil—Rash—Cisplatin—bone cancer	6.86e-05	0.00121	CcSEcCtD
Fluorouracil—Dermatitis—Cisplatin—bone cancer	6.86e-05	0.00121	CcSEcCtD
Fluorouracil—Erythema—Epirubicin—bone cancer	6.85e-05	0.00121	CcSEcCtD
Fluorouracil—Anaemia—Methotrexate—bone cancer	6.77e-05	0.0012	CcSEcCtD
Fluorouracil—Leukopenia—Methotrexate—bone cancer	6.55e-05	0.00116	CcSEcCtD
Fluorouracil—Arrhythmia—Doxorubicin—bone cancer	6.5e-05	0.00115	CcSEcCtD
Fluorouracil—Nausea—Cisplatin—bone cancer	6.47e-05	0.00114	CcSEcCtD
Fluorouracil—Vision blurred—Epirubicin—bone cancer	6.46e-05	0.00114	CcSEcCtD
Fluorouracil—Alopecia—Doxorubicin—bone cancer	6.43e-05	0.00114	CcSEcCtD
Fluorouracil—Convulsion—Methotrexate—bone cancer	6.34e-05	0.00112	CcSEcCtD
Fluorouracil—Erythema—Doxorubicin—bone cancer	6.34e-05	0.00112	CcSEcCtD
Fluorouracil—Anaemia—Epirubicin—bone cancer	6.33e-05	0.00112	CcSEcCtD
Fluorouracil—Chest pain—Methotrexate—bone cancer	6.23e-05	0.0011	CcSEcCtD
Fluorouracil—Myalgia—Methotrexate—bone cancer	6.23e-05	0.0011	CcSEcCtD
Fluorouracil—Discomfort—Methotrexate—bone cancer	6.16e-05	0.00109	CcSEcCtD
Fluorouracil—Leukopenia—Epirubicin—bone cancer	6.13e-05	0.00109	CcSEcCtD
Fluorouracil—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	6.06e-05	0.000765	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—ENO2—bone cancer	6.04e-05	0.000762	CbGpPWpGaD
Fluorouracil—Confusional state—Methotrexate—bone cancer	6.02e-05	0.00107	CcSEcCtD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6e-05	0.000757	CbGpPWpGaD
Fluorouracil—Anaphylactic shock—Methotrexate—bone cancer	5.97e-05	0.00106	CcSEcCtD
Fluorouracil—Vision blurred—Doxorubicin—bone cancer	5.97e-05	0.00106	CcSEcCtD
Fluorouracil—Convulsion—Epirubicin—bone cancer	5.94e-05	0.00105	CcSEcCtD
Fluorouracil—Infection—Methotrexate—bone cancer	5.94e-05	0.00105	CcSEcCtD
Fluorouracil—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	5.93e-05	0.000748	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.91e-05	0.000746	CbGpPWpGaD
Fluorouracil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	5.88e-05	0.000741	CbGpPWpGaD
Fluorouracil—Nervous system disorder—Methotrexate—bone cancer	5.86e-05	0.00104	CcSEcCtD
Fluorouracil—Anaemia—Doxorubicin—bone cancer	5.86e-05	0.00104	CcSEcCtD
Fluorouracil—Thrombocytopenia—Methotrexate—bone cancer	5.85e-05	0.00104	CcSEcCtD
Fluorouracil—Myalgia—Epirubicin—bone cancer	5.83e-05	0.00103	CcSEcCtD
Fluorouracil—Chest pain—Epirubicin—bone cancer	5.83e-05	0.00103	CcSEcCtD
Fluorouracil—ALB—Folate Metabolism—DHFR—bone cancer	5.83e-05	0.000736	CbGpPWpGaD
Fluorouracil—Discomfort—Epirubicin—bone cancer	5.76e-05	0.00102	CcSEcCtD
Fluorouracil—Anorexia—Methotrexate—bone cancer	5.69e-05	0.00101	CcSEcCtD
Fluorouracil—Leukopenia—Doxorubicin—bone cancer	5.67e-05	0.001	CcSEcCtD
Fluorouracil—Confusional state—Epirubicin—bone cancer	5.64e-05	0.000998	CcSEcCtD
Fluorouracil—UPP1—Metabolism—ENO2—bone cancer	5.61e-05	0.000709	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—ENO2—bone cancer	5.61e-05	0.000709	CbGpPWpGaD
Fluorouracil—ABCC5—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.61e-05	0.000708	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—DHFR—bone cancer	5.6e-05	0.000707	CbGpPWpGaD
Fluorouracil—Oedema—Epirubicin—bone cancer	5.59e-05	0.00099	CcSEcCtD
Fluorouracil—Anaphylactic shock—Epirubicin—bone cancer	5.59e-05	0.00099	CcSEcCtD
Fluorouracil—Hypotension—Methotrexate—bone cancer	5.58e-05	0.000988	CcSEcCtD
Fluorouracil—Infection—Epirubicin—bone cancer	5.55e-05	0.000983	CcSEcCtD
Fluorouracil—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	5.53e-05	0.000697	CbGpPWpGaD
Fluorouracil—Convulsion—Doxorubicin—bone cancer	5.49e-05	0.000972	CcSEcCtD
Fluorouracil—Nervous system disorder—Epirubicin—bone cancer	5.48e-05	0.00097	CcSEcCtD
Fluorouracil—Thrombocytopenia—Epirubicin—bone cancer	5.47e-05	0.000969	CcSEcCtD
Fluorouracil—Tachycardia—Epirubicin—bone cancer	5.46e-05	0.000966	CcSEcCtD
Fluorouracil—TYMS—Cell Cycle—TUBB4B—bone cancer	5.45e-05	0.000688	CbGpPWpGaD
Fluorouracil—Musculoskeletal discomfort—Methotrexate—bone cancer	5.44e-05	0.000963	CcSEcCtD
Fluorouracil—Insomnia—Methotrexate—bone cancer	5.4e-05	0.000956	CcSEcCtD
Fluorouracil—Chest pain—Doxorubicin—bone cancer	5.4e-05	0.000955	CcSEcCtD
Fluorouracil—Myalgia—Doxorubicin—bone cancer	5.4e-05	0.000955	CcSEcCtD
Fluorouracil—Paraesthesia—Methotrexate—bone cancer	5.36e-05	0.000949	CcSEcCtD
Fluorouracil—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.36e-05	0.000677	CbGpPWpGaD
Fluorouracil—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	5.33e-05	0.000673	CbGpPWpGaD
Fluorouracil—Discomfort—Doxorubicin—bone cancer	5.33e-05	0.000944	CcSEcCtD
Fluorouracil—Anorexia—Epirubicin—bone cancer	5.33e-05	0.000943	CcSEcCtD
Fluorouracil—Dyspnoea—Methotrexate—bone cancer	5.33e-05	0.000943	CcSEcCtD
Fluorouracil—Somnolence—Methotrexate—bone cancer	5.31e-05	0.00094	CcSEcCtD
Fluorouracil—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.29e-05	0.000668	CbGpPWpGaD
Fluorouracil—ABCC3—NRF2 pathway—TGFBR2—bone cancer	5.26e-05	0.000664	CbGpPWpGaD
Fluorouracil—ABCC3—NRF2 pathway—GSTP1—bone cancer	5.26e-05	0.000664	CbGpPWpGaD
Fluorouracil—Dyspepsia—Methotrexate—bone cancer	5.26e-05	0.000931	CcSEcCtD
Fluorouracil—UMPS—Metabolism—GNA11—bone cancer	5.24e-05	0.000661	CbGpPWpGaD
Fluorouracil—Hypotension—Epirubicin—bone cancer	5.22e-05	0.000925	CcSEcCtD
Fluorouracil—Confusional state—Doxorubicin—bone cancer	5.22e-05	0.000923	CcSEcCtD
Fluorouracil—UPP1—Metabolism—DHFR—bone cancer	5.21e-05	0.000657	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—DHFR—bone cancer	5.21e-05	0.000657	CbGpPWpGaD
Fluorouracil—Decreased appetite—Methotrexate—bone cancer	5.19e-05	0.000919	CcSEcCtD
Fluorouracil—Oedema—Doxorubicin—bone cancer	5.17e-05	0.000916	CcSEcCtD
Fluorouracil—Anaphylactic shock—Doxorubicin—bone cancer	5.17e-05	0.000916	CcSEcCtD
Fluorouracil—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	5.17e-05	0.000652	CbGpPWpGaD
Fluorouracil—Gastrointestinal disorder—Methotrexate—bone cancer	5.16e-05	0.000913	CcSEcCtD
Fluorouracil—Infection—Doxorubicin—bone cancer	5.14e-05	0.00091	CcSEcCtD
Fluorouracil—Pain—Methotrexate—bone cancer	5.11e-05	0.000904	CcSEcCtD
Fluorouracil—ALB—Platelet degranulation—SPARC—bone cancer	5.11e-05	0.000645	CbGpPWpGaD
Fluorouracil—Musculoskeletal discomfort—Epirubicin—bone cancer	5.09e-05	0.000902	CcSEcCtD
Fluorouracil—Nervous system disorder—Doxorubicin—bone cancer	5.07e-05	0.000898	CcSEcCtD
Fluorouracil—Thrombocytopenia—Doxorubicin—bone cancer	5.06e-05	0.000896	CcSEcCtD
Fluorouracil—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	5.06e-05	0.000639	CbGpPWpGaD
Fluorouracil—TYMS—G1/S Transition—RB1—bone cancer	5.06e-05	0.000639	CbGpPWpGaD
Fluorouracil—Insomnia—Epirubicin—bone cancer	5.06e-05	0.000895	CcSEcCtD
Fluorouracil—Tachycardia—Doxorubicin—bone cancer	5.05e-05	0.000894	CcSEcCtD
Fluorouracil—MTHFR—Metabolism—NDUFA12—bone cancer	5.04e-05	0.000636	CbGpPWpGaD
Fluorouracil—Paraesthesia—Epirubicin—bone cancer	5.02e-05	0.000889	CcSEcCtD
Fluorouracil—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	5.01e-05	0.000633	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.01e-05	0.000633	CbGpPWpGaD
Fluorouracil—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	5.01e-05	0.000632	CbGpPWpGaD
Fluorouracil—Dyspnoea—Epirubicin—bone cancer	4.98e-05	0.000882	CcSEcCtD
Fluorouracil—Somnolence—Epirubicin—bone cancer	4.97e-05	0.00088	CcSEcCtD
Fluorouracil—ABCC4—NRF2 pathway—GSTP1—bone cancer	4.95e-05	0.000624	CbGpPWpGaD
Fluorouracil—ABCC4—NRF2 pathway—TGFBR2—bone cancer	4.95e-05	0.000624	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—RFC1—bone cancer	4.94e-05	0.000624	CbGpPWpGaD
Fluorouracil—Anorexia—Doxorubicin—bone cancer	4.93e-05	0.000873	CcSEcCtD
Fluorouracil—Feeling abnormal—Methotrexate—bone cancer	4.92e-05	0.000871	CcSEcCtD
Fluorouracil—Dyspepsia—Epirubicin—bone cancer	4.92e-05	0.000871	CcSEcCtD
Fluorouracil—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	4.91e-05	0.000619	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—GNA11—bone cancer	4.87e-05	0.000614	CbGpPWpGaD
Fluorouracil—UPP1—Metabolism—GNA11—bone cancer	4.87e-05	0.000614	CbGpPWpGaD
Fluorouracil—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	4.87e-05	0.000614	CbGpPWpGaD
Fluorouracil—Decreased appetite—Epirubicin—bone cancer	4.86e-05	0.00086	CcSEcCtD
Fluorouracil—ABCC5—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.85e-05	0.000611	CbGpPWpGaD
Fluorouracil—Hypotension—Doxorubicin—bone cancer	4.83e-05	0.000856	CcSEcCtD
Fluorouracil—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.83e-05	0.000609	CbGpPWpGaD
Fluorouracil—Gastrointestinal disorder—Epirubicin—bone cancer	4.83e-05	0.000854	CcSEcCtD
Fluorouracil—Pain—Epirubicin—bone cancer	4.78e-05	0.000846	CcSEcCtD
Fluorouracil—MTHFR—Folate Metabolism—TP53—bone cancer	4.77e-05	0.000602	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—CYP3A4—bone cancer	4.75e-05	0.000599	CbGpPWpGaD
Fluorouracil—Urticaria—Methotrexate—bone cancer	4.75e-05	0.00084	CcSEcCtD
Fluorouracil—Body temperature increased—Methotrexate—bone cancer	4.72e-05	0.000836	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.71e-05	0.000834	CcSEcCtD
Fluorouracil—Insomnia—Doxorubicin—bone cancer	4.68e-05	0.000828	CcSEcCtD
Fluorouracil—Paraesthesia—Doxorubicin—bone cancer	4.65e-05	0.000822	CcSEcCtD
Fluorouracil—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	4.61e-05	0.000582	CbGpPWpGaD
Fluorouracil—Dyspnoea—Doxorubicin—bone cancer	4.61e-05	0.000816	CcSEcCtD
Fluorouracil—Feeling abnormal—Epirubicin—bone cancer	4.61e-05	0.000815	CcSEcCtD
Fluorouracil—Somnolence—Doxorubicin—bone cancer	4.6e-05	0.000814	CcSEcCtD
Fluorouracil—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	4.58e-05	0.000578	CbGpPWpGaD
Fluorouracil—Dyspepsia—Doxorubicin—bone cancer	4.55e-05	0.000806	CcSEcCtD
Fluorouracil—Decreased appetite—Doxorubicin—bone cancer	4.5e-05	0.000796	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Doxorubicin—bone cancer	4.47e-05	0.00079	CcSEcCtD
Fluorouracil—Urticaria—Epirubicin—bone cancer	4.44e-05	0.000786	CcSEcCtD
Fluorouracil—Pain—Doxorubicin—bone cancer	4.42e-05	0.000783	CcSEcCtD
Fluorouracil—Body temperature increased—Epirubicin—bone cancer	4.42e-05	0.000782	CcSEcCtD
Fluorouracil—UPP2—Metabolism—CYP3A4—bone cancer	4.41e-05	0.000557	CbGpPWpGaD
Fluorouracil—UPP1—Metabolism—CYP3A4—bone cancer	4.41e-05	0.000557	CbGpPWpGaD
Fluorouracil—Hypersensitivity—Methotrexate—bone cancer	4.4e-05	0.000779	CcSEcCtD
Fluorouracil—ABCC5—Metabolism—NDUFA12—bone cancer	4.39e-05	0.000554	CbGpPWpGaD
Fluorouracil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	4.36e-05	0.000551	CbGpPWpGaD
Fluorouracil—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.35e-05	0.000549	CbGpPWpGaD
Fluorouracil—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.31e-05	0.000544	CbGpPWpGaD
Fluorouracil—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	4.27e-05	0.000538	CbGpPWpGaD
Fluorouracil—Feeling abnormal—Doxorubicin—bone cancer	4.26e-05	0.000754	CcSEcCtD
Fluorouracil—Pruritus—Methotrexate—bone cancer	4.23e-05	0.000748	CcSEcCtD
Fluorouracil—MTHFR—Metabolism—NT5C3A—bone cancer	4.18e-05	0.000527	CbGpPWpGaD
Fluorouracil—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.17e-05	0.000526	CbGpPWpGaD
Fluorouracil—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	4.15e-05	0.000524	CbGpPWpGaD
Fluorouracil—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.14e-05	0.000522	CbGpPWpGaD
Fluorouracil—Hypersensitivity—Epirubicin—bone cancer	4.12e-05	0.000729	CcSEcCtD
Fluorouracil—Urticaria—Doxorubicin—bone cancer	4.11e-05	0.000727	CcSEcCtD
Fluorouracil—Body temperature increased—Doxorubicin—bone cancer	4.09e-05	0.000724	CcSEcCtD
Fluorouracil—Diarrhoea—Methotrexate—bone cancer	4.09e-05	0.000723	CcSEcCtD
Fluorouracil—UMPS—Metabolism—GSTP1—bone cancer	4.06e-05	0.000512	CbGpPWpGaD
Fluorouracil—Pruritus—Epirubicin—bone cancer	3.96e-05	0.0007	CcSEcCtD
Fluorouracil—Dizziness—Methotrexate—bone cancer	3.95e-05	0.000699	CcSEcCtD
Fluorouracil—TYMS—Metabolism—NDUFA12—bone cancer	3.91e-05	0.000493	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—ENO2—bone cancer	3.89e-05	0.000491	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—ENO2—bone cancer	3.89e-05	0.000491	CbGpPWpGaD
Fluorouracil—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.89e-05	0.000491	CbGpPWpGaD
Fluorouracil—Diarrhoea—Epirubicin—bone cancer	3.83e-05	0.000677	CcSEcCtD
Fluorouracil—Hypersensitivity—Doxorubicin—bone cancer	3.81e-05	0.000675	CcSEcCtD
Fluorouracil—Vomiting—Methotrexate—bone cancer	3.8e-05	0.000672	CcSEcCtD
Fluorouracil—UPP1—Metabolism—GSTP1—bone cancer	3.77e-05	0.000476	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—GSTP1—bone cancer	3.77e-05	0.000476	CbGpPWpGaD
Fluorouracil—Rash—Methotrexate—bone cancer	3.77e-05	0.000667	CcSEcCtD
Fluorouracil—Dermatitis—Methotrexate—bone cancer	3.76e-05	0.000666	CcSEcCtD
Fluorouracil—Headache—Methotrexate—bone cancer	3.74e-05	0.000662	CcSEcCtD
Fluorouracil—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	3.73e-05	0.000471	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.72e-05	0.000469	CbGpPWpGaD
Fluorouracil—Dizziness—Epirubicin—bone cancer	3.7e-05	0.000654	CcSEcCtD
Fluorouracil—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	3.68e-05	0.000464	CbGpPWpGaD
Fluorouracil—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	3.68e-05	0.000464	CbGpPWpGaD
Fluorouracil—Pruritus—Doxorubicin—bone cancer	3.66e-05	0.000648	CcSEcCtD
Fluorouracil—ABCC5—Metabolism—NT5C3A—bone cancer	3.64e-05	0.000459	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—DHFR—bone cancer	3.61e-05	0.000456	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—DHFR—bone cancer	3.61e-05	0.000456	CbGpPWpGaD
Fluorouracil—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.57e-05	0.000451	CbGpPWpGaD
Fluorouracil—TYMS—Circadian rythm related genes—CDK4—bone cancer	3.57e-05	0.00045	CbGpPWpGaD
Fluorouracil—Vomiting—Epirubicin—bone cancer	3.55e-05	0.000629	CcSEcCtD
Fluorouracil—Nausea—Methotrexate—bone cancer	3.55e-05	0.000628	CcSEcCtD
Fluorouracil—Diarrhoea—Doxorubicin—bone cancer	3.54e-05	0.000626	CcSEcCtD
Fluorouracil—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.54e-05	0.000447	CbGpPWpGaD
Fluorouracil—Rash—Epirubicin—bone cancer	3.53e-05	0.000624	CcSEcCtD
Fluorouracil—Dermatitis—Epirubicin—bone cancer	3.52e-05	0.000623	CcSEcCtD
Fluorouracil—Headache—Epirubicin—bone cancer	3.5e-05	0.00062	CcSEcCtD
Fluorouracil—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	3.43e-05	0.000432	CbGpPWpGaD
Fluorouracil—Dizziness—Doxorubicin—bone cancer	3.42e-05	0.000605	CcSEcCtD
Fluorouracil—CYP2A6—Biological oxidations—CYP3A4—bone cancer	3.38e-05	0.000427	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—GNA11—bone cancer	3.37e-05	0.000426	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—GNA11—bone cancer	3.37e-05	0.000426	CbGpPWpGaD
Fluorouracil—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.36e-05	0.000424	CbGpPWpGaD
Fluorouracil—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	3.34e-05	0.000422	CbGpPWpGaD
Fluorouracil—Nausea—Epirubicin—bone cancer	3.32e-05	0.000588	CcSEcCtD
Fluorouracil—CYP2A6—NRF2 pathway—GSTP1—bone cancer	3.3e-05	0.000416	CbGpPWpGaD
Fluorouracil—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	3.3e-05	0.000416	CbGpPWpGaD
Fluorouracil—Vomiting—Doxorubicin—bone cancer	3.29e-05	0.000582	CcSEcCtD
Fluorouracil—Rash—Doxorubicin—bone cancer	3.26e-05	0.000577	CcSEcCtD
Fluorouracil—Dermatitis—Doxorubicin—bone cancer	3.26e-05	0.000577	CcSEcCtD
Fluorouracil—Headache—Doxorubicin—bone cancer	3.24e-05	0.000574	CcSEcCtD
Fluorouracil—TYMS—Metabolism—NT5C3A—bone cancer	3.24e-05	0.000409	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—NDUFA12—bone cancer	3.24e-05	0.000408	CbGpPWpGaD
Fluorouracil—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	3.2e-05	0.000404	CbGpPWpGaD
Fluorouracil—Nausea—Doxorubicin—bone cancer	3.07e-05	0.000544	CcSEcCtD
Fluorouracil—TYMS—Cell Cycle—DHFR—bone cancer	3.06e-05	0.000387	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—CYP3A4—bone cancer	3.06e-05	0.000386	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—CYP3A4—bone cancer	3.06e-05	0.000386	CbGpPWpGaD
Fluorouracil—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.02e-05	0.000382	CbGpPWpGaD
Fluorouracil—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	2.97e-05	0.000374	CbGpPWpGaD
Fluorouracil—CYP2A6—Biological oxidations—GSTP1—bone cancer	2.89e-05	0.000365	CbGpPWpGaD
Fluorouracil—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.85e-05	0.00036	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—ENO2—bone cancer	2.77e-05	0.00035	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.76e-05	0.000348	CbGpPWpGaD
Fluorouracil—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	2.75e-05	0.000347	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—NT5C3A—bone cancer	2.68e-05	0.000338	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.66e-05	0.000335	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—GSTP1—bone cancer	2.62e-05	0.00033	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—GSTP1—bone cancer	2.62e-05	0.00033	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—SPARC—bone cancer	2.58e-05	0.000326	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—DHFR—bone cancer	2.57e-05	0.000325	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—CHEK2—bone cancer	2.56e-05	0.000323	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	2.49e-05	0.000314	CbGpPWpGaD
Fluorouracil—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.46e-05	0.000311	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—GNA11—bone cancer	2.4e-05	0.000303	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.4e-05	0.000302	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—GNA11—bone cancer	2.36e-05	0.000298	CbGpPWpGaD
Fluorouracil—CYP1A2—Phase II conjugation—GSTP1—bone cancer	2.35e-05	0.000296	CbGpPWpGaD
Fluorouracil—CYP2C8—Biological oxidations—CYP3A4—bone cancer	2.31e-05	0.000291	CbGpPWpGaD
Fluorouracil—TYMS—Circadian rythm related genes—JUN—bone cancer	2.3e-05	0.00029	CbGpPWpGaD
Fluorouracil—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	2.28e-05	0.000287	CbGpPWpGaD
Fluorouracil—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	2.27e-05	0.000286	CbGpPWpGaD
Fluorouracil—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	2.24e-05	0.000282	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—NDUFA12—bone cancer	2.23e-05	0.000281	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—ENO2—bone cancer	2.18e-05	0.000276	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—CYP3A4—bone cancer	2.18e-05	0.000275	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—BRCA2—bone cancer	2.17e-05	0.000274	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—IL3—bone cancer	2.14e-05	0.00027	CbGpPWpGaD
Fluorouracil—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	2.12e-05	0.000268	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—PTGS2—bone cancer	2.1e-05	0.000265	CbGpPWpGaD
Fluorouracil—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	2.07e-05	0.000262	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	2.04e-05	0.000258	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—DHFR—bone cancer	2.03e-05	0.000256	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—NDUFA12—bone cancer	2.03e-05	0.000256	CbGpPWpGaD
Fluorouracil—CYP2C8—Biological oxidations—GSTP1—bone cancer	1.98e-05	0.000249	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—PTGS2—bone cancer	1.96e-05	0.000247	CbGpPWpGaD
Fluorouracil—UPP1—Metabolism—PTGS2—bone cancer	1.96e-05	0.000247	CbGpPWpGaD
Fluorouracil—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	1.95e-05	0.000246	CbGpPWpGaD
Fluorouracil—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	1.91e-05	0.000241	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—ENO2—bone cancer	1.9e-05	0.00024	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.88e-05	0.000238	CbGpPWpGaD
Fluorouracil—CYP2C9—Biological oxidations—CYP3A4—bone cancer	1.88e-05	0.000237	CbGpPWpGaD
Fluorouracil—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	1.88e-05	0.000237	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—GSTP1—bone cancer	1.86e-05	0.000235	CbGpPWpGaD
Fluorouracil—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	1.85e-05	0.000234	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—NT5C3A—bone cancer	1.85e-05	0.000233	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	1.84e-05	0.000233	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—ENO2—bone cancer	1.83e-05	0.000231	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	1.8e-05	0.000227	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—DHFR—bone cancer	1.76e-05	0.000223	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.76e-05	0.000222	CbGpPWpGaD
Fluorouracil—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	1.74e-05	0.000219	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—DHFR—bone cancer	1.7e-05	0.000214	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—NT5C3A—bone cancer	1.68e-05	0.000212	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—CDK4—bone cancer	1.61e-05	0.000203	CbGpPWpGaD
Fluorouracil—CYP2C9—Biological oxidations—GSTP1—bone cancer	1.61e-05	0.000203	CbGpPWpGaD
Fluorouracil—CYP1A2—Biological oxidations—CYP3A4—bone cancer	1.61e-05	0.000203	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—ENO2—bone cancer	1.59e-05	0.000201	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—GNA11—bone cancer	1.59e-05	0.0002	CbGpPWpGaD
Fluorouracil—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	1.59e-05	0.0002	CbGpPWpGaD
Fluorouracil—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	1.58e-05	0.0002	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.58e-05	0.0002	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	1.56e-05	0.000197	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.52e-05	0.000192	CbGpPWpGaD
Fluorouracil—TYMS—Circadian rythm related genes—TP53—bone cancer	1.52e-05	0.000192	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—DHFR—bone cancer	1.48e-05	0.000186	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—TGFBR2—bone cancer	1.47e-05	0.000185	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	1.45e-05	0.000183	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	1.45e-05	0.000183	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—CYP3A4—bone cancer	1.44e-05	0.000181	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—ENO2—bone cancer	1.42e-05	0.000179	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—PLAU—bone cancer	1.4e-05	0.000177	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—RB1—bone cancer	1.4e-05	0.000177	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—NDUFA12—bone cancer	1.38e-05	0.000175	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—GNA11—bone cancer	1.38e-05	0.000174	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—NDUFA12—bone cancer	1.38e-05	0.000174	CbGpPWpGaD
Fluorouracil—CYP1A2—Biological oxidations—GSTP1—bone cancer	1.37e-05	0.000173	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—PTGS2—bone cancer	1.36e-05	0.000171	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—PTGS2—bone cancer	1.36e-05	0.000171	CbGpPWpGaD
Fluorouracil—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	1.35e-05	0.000171	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—DHFR—bone cancer	1.32e-05	0.000166	CbGpPWpGaD
Fluorouracil—ALB—Folate Metabolism—TP53—bone cancer	1.3e-05	0.000164	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—TGFBR2—bone cancer	1.28e-05	0.000161	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000158	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—GNA11—bone cancer	1.23e-05	0.000155	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—GSTP1—bone cancer	1.23e-05	0.000155	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—MDM2—bone cancer	1.19e-05	0.000151	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—ENO2—bone cancer	1.17e-05	0.000148	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—SPARC—bone cancer	1.17e-05	0.000147	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—NT5C3A—bone cancer	1.15e-05	0.000145	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—NT5C3A—bone cancer	1.14e-05	0.000144	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—NDUFA12—bone cancer	1.13e-05	0.000142	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—CYP3A4—bone cancer	1.12e-05	0.000141	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—DHFR—bone cancer	1.09e-05	0.000137	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—GSTP1—bone cancer	1.07e-05	0.000135	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—GNA11—bone cancer	1.07e-05	0.000135	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—GNA11—bone cancer	1.02e-05	0.000128	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—KIT—bone cancer	1e-05	0.000126	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—IL3—bone cancer	9.69e-06	0.000122	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—PTGS2—bone cancer	9.66e-06	0.000122	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—NDUFA12—bone cancer	9.63e-06	0.000121	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—GSTP1—bone cancer	9.54e-06	0.00012	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—BRAF—bone cancer	9.42e-06	0.000119	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—NT5C3A—bone cancer	9.34e-06	0.000118	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—CYP3A4—bone cancer	9.23e-06	0.000116	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.18e-06	0.000116	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—KIT—bone cancer	8.72e-06	0.00011	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—BRAF—bone cancer	8.2e-06	0.000103	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—ENO2—bone cancer	8.1e-06	0.000102	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—NT5C3A—bone cancer	7.98e-06	0.000101	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—GSTP1—bone cancer	7.89e-06	9.96e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—MDM2—bone cancer	7.89e-06	9.96e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—PTGS2—bone cancer	7.61e-06	9.6e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—DHFR—bone cancer	7.51e-06	9.48e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—ENO2—bone cancer	7.36e-06	9.28e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—GNA11—bone cancer	7.02e-06	8.86e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—MDM2—bone cancer	6.87e-06	8.67e-05	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—TP53—bone cancer	6.84e-06	8.64e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—DHFR—bone cancer	6.82e-06	8.61e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—PTGS2—bone cancer	6.62e-06	8.36e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—GNA11—bone cancer	6.38e-06	8.05e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—PTGS2—bone cancer	6.37e-06	8.04e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—CYP3A4—bone cancer	6.36e-06	8.03e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—PLAU—bone cancer	6.35e-06	8.02e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—CYP3A4—bone cancer	5.78e-06	7.3e-05	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—TP53—bone cancer	5.64e-06	7.12e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—PTGS2—bone cancer	5.55e-06	7e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—GSTP1—bone cancer	5.44e-06	6.87e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—EGFR—bone cancer	5.39e-06	6.81e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ENO2—bone cancer	5.02e-06	6.34e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ENO2—bone cancer	5e-06	6.3e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—GSTP1—bone cancer	4.94e-06	6.24e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—PTGS2—bone cancer	4.94e-06	6.23e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—EGFR—bone cancer	4.7e-06	5.93e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—DHFR—bone cancer	4.66e-06	5.88e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—DHFR—bone cancer	4.63e-06	5.85e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GNA11—bone cancer	4.36e-06	5.5e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GNA11—bone cancer	4.33e-06	5.47e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—PTGS2—bone cancer	4.09e-06	5.16e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ENO2—bone cancer	4.09e-06	5.16e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CYP3A4—bone cancer	3.95e-06	4.98e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.93e-06	4.96e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CYP3A4—bone cancer	3.93e-06	4.96e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.91e-06	4.93e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—DHFR—bone cancer	3.79e-06	4.79e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GNA11—bone cancer	3.55e-06	4.47e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ENO2—bone cancer	3.49e-06	4.41e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GSTP1—bone cancer	3.38e-06	4.26e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GSTP1—bone cancer	3.36e-06	4.24e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—DHFR—bone cancer	3.24e-06	4.09e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CYP3A4—bone cancer	3.21e-06	4.06e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.2e-06	4.04e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GNA11—bone cancer	3.03e-06	3.82e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PTGS2—bone cancer	2.82e-06	3.56e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GSTP1—bone cancer	2.75e-06	3.47e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CYP3A4—bone cancer	2.75e-06	3.47e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.73e-06	3.45e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PTGS2—bone cancer	2.56e-06	3.23e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—TP53—bone cancer	2.55e-06	3.22e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GSTP1—bone cancer	2.35e-06	2.96e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PTGS2—bone cancer	1.75e-06	2.21e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PTGS2—bone cancer	1.74e-06	2.2e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PTGS2—bone cancer	1.42e-06	1.8e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PTGS2—bone cancer	1.22e-06	1.54e-05	CbGpPWpGaD
